The state of Minnesota currently has 4 active clinical trials seeking participants for Atopic Dermatitis research studies. These trials are conducted in various cities, including Minneapolis, Rochester, Saint Paul and Duluth.
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/08/2024
Locations: Up0110 114, Minneapolis, Minnesota
Conditions: Atopic Dermatitis
Study of TDM-180935 in Atopic Dermatitis Patients
Recruiting
Randomized, Vehicle-controlled, Parallel Group Study of TDM-180935 in Atopic Dermatitis Patients
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Site 4, New Brighton, Minnesota
Conditions: Atopic Dermatitis
Bone Health in Patients With Atopic Dermatitis
Recruiting
This study examines the bone health in children with atopic dermatitis
Gender:
All
Ages:
Between 5 years and 17 years
Trial Updated:
03/27/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Atopic Dermatitis, Eczema
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
All
Ages:
All
Trial Updated:
03/19/2024
Locations: University of Minnesota, Minneapolis, Minnesota +1 locations
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria